OSLO, 28 March 2023: EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth: EXTX),
a clinical stage precision health company utilising Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today presents data from two patients
with liver metastases of colorectal cancer origin treated with ACT in the
clinical Phase I ACTIVATE trial.

The presented radiological results from these two patients suggest an improved
response to standard of care chemotherapy in the tumours that are exposed to ACT
treatment. This aligns well with the preclinical evidence that ACT treatment can
enhance the response to several chemotherapies in different cancer models.
 
Based on the initial clinical results, ACT treatment does not add to the safety
or tolerability burden on patients. No adverse events considered related to the
ACT treatment were seen in these two patients when ACT was combined with
standard of care chemotherapy. 

The principal investigator of the ACTIVATE study, Prof. Dr. Udai Banerji
comments: "Results of the Phase I study have given us several insights, most
importantly that the treatment did not reveal any unexpected side effects either
on its own or worsen the side effects of chemotherapy in the treated patients.
The results also suggest a positive tumour response associated with the ACT
treatment. This trial will set the stage for diversifying the use of this
technology platform to a wide range of systemic therapies across multiple tumour
types." 

So far, seven patients have been enrolled in the study and encouraging insights
have been gained from these patients.

EXACT Therapeutics is now in the process of completing the dose-escalation part
of the study and will thereafter randomise up to 20 patients to two dose levels
of ACT in an expansion part of the Phase I ACTIVATE trial. 

For more information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

About EXACT-Tx

EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®).  ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases. www.exact-tx.com

About the Science & Technology Event 28 March 2023

EXACT-Tx will hold a Science & Technology Event at 13:00-15:00 CET on 28 March
at the Faros meeting room in the Oslo Science Park.  The executive team, as well
as Anders Wold and Sir William Castell, Chair and Nonexecutive Director of the
Board, respectively, will introduce EXACT-Tx and the ACT® platform technology.
Prof. Udai Banerji, Principal Investigator of the ACTIVATE study, will present
clinical case reports from the study. 

About ACT®

o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas and product classes. 

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.